12,112 Shares in Johnson & Johnson (NYSE:JNJ) Acquired by CFO4Life L.P.

Posted by on Mar 21st, 2023

CFO4Life L.P. purchased a new position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 12,112 shares of the company’s stock, valued at approximately $2,140,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Lincoln Capital Corp raised its holdings in Johnson & Johnson by 15.9% during the 3rd quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock worth $218,000 after purchasing an additional 183 shares during the last quarter. Ieq Capital LLC increased its stake in shares of Johnson & Johnson by 5.1% in the 3rd quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock valued at $20,912,000 after acquiring an additional 6,154 shares in the last quarter. RFG Advisory LLC increased its stake in shares of Johnson & Johnson by 2.7% in the 3rd quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock valued at $3,900,000 after acquiring an additional 594 shares in the last quarter. FDx Advisors Inc. increased its stake in shares of Johnson & Johnson by 0.3% in the 3rd quarter. FDx Advisors Inc. now owns 50,421 shares of the company’s stock valued at $8,237,000 after acquiring an additional 153 shares in the last quarter. Finally, HM Payson & Co. increased its stake in shares of Johnson & Johnson by 3.2% in the 3rd quarter. HM Payson & Co. now owns 783,538 shares of the company’s stock valued at $127,999,000 after acquiring an additional 24,188 shares in the last quarter. Institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Price Performance

JNJ opened at $153.89 on Tuesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77. The company has a market capitalization of $400.77 billion, a price-to-earnings ratio of 22.83, a P/E/G ratio of 2.63 and a beta of 0.54. The firm’s fifty day moving average price is $161.53 and its two-hundred day moving average price is $167.88. Johnson & Johnson has a 1 year low of $150.71 and a 1 year high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. The firm had revenue of $23.71 billion for the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The business’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.13 EPS. As a group, analysts anticipate that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st were paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.94%. The ex-dividend date was Friday, February 17th. Johnson & Johnson’s payout ratio is 67.06%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on JNJ. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Guggenheim began coverage on shares of Johnson & Johnson in a research note on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price objective for the company. Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $176.00 to $180.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 25th. StockNews.com initiated coverage on shares of Johnson & Johnson in a research note on Thursday, March 16th. They set a “strong-buy” rating for the company. Finally, Piper Sandler decreased their price target on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $174.73.

Insider Activity

In related news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Featured Articles

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.